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Methods: We prospectively enrolled 535 non-diabetic patient (pts) with AMI (age 60 ±
13). Fasting glucose (FG) was measured on the first morning after admission, and
divided into tertiles. Ejection fraction (EF) was determined by echocardiography on day 2
or 3. Adjusted 30-day mortality was evaluated using multiple logistic regression with the
following covariates: age, gender, hypertension, smoking, prior AMI, Killip class, heart
rate and systolic blood pressure, ST-elevation infarction, anterior infarction, peak CK, and
use of reperfusion therapy.
Results: At 30 days, 6 deaths (3%) occurred in pts in the lowest FG tertile (<98 mg/dL),
11 (6%) in pts in the middle FG tertile (98-118 mg/dL), and 35 (20%) in pts in the highest
FG tertile (>118 mg/dL) (Figure). The risk of 30-day mortality increased with increasing
tertiles of FG (P trend = 0.02), with an OR of 3.2 for pts in the upper FG tertile (95% CI
1.5-6.8, p = 0.002). Further adjustment for EF gave similar results (OR = 2.8, 95% CI 1.3-
6.2, p = 0.01).
Conclusion: In pts with AMI stress hyperglycemia is a strong predictor of 30-day mortal-
ity independent of infarct size and other traditional predictors of outcome. Increased risk
appears to be associated even with FG in the upper normal range.
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827-3 Women With Diabetes Mellitus Have the Greatest 
Reduction in Myocardial Infarction Mortality Over the 
Past Decade: Evaluation of 1,428,596 Patients Enrolled 
in the National Registry of Myocardial Infarction 2, 3, 
and 4 From 1994-2002
Darren K. McGuire, Amit Khera, James A. de Lemos, Eric D. Peterson, John J. Warner, 
Lori S. Parsons, William J. Rogers, John G. Canto, for the National Registry of 
Myocardial Infarctions Investigators, University of Texas-Southwestern Medical Center, 
Dallas, TX, University of Alabama, Birmingham, AL
Background: Analyses from NHANES showed a decline in cardiovascular (CV) mortality
in the 1970s-80s, but among patients with diabetes mellitus (DM), the rate of decline was
attenuated among men (less improvement) and women (no improvement). We sought to
examine the relation between sex, DM, and hospital mortality in the setting of contempo-
rary care for myocardial infarction (MI).
Methods/Results: We analyzed data from 1,428,596 patients with MI enrolled in NRMI
2, 3, & 4 from 1994-2002. DM was present in 410,223 patients (29%), increased in prev-
alence over the study period (26% to 31%), and was associated with higher adjusted
hospital mortality (13.8% vs. 10.9%; adjusted OR=1.3 [95% CI 1.3-1.33]. Use of ASA, β-
blockers, and ACE inhibitors within 24 hours of admission increased yearly for both DM
and non-DM cohorts. Overall hospital mortality declined between 1994-2002 (19.7%; p
for trend<0.001), with a greater rate of decline among DM vs. non-DM patients (26.4%
vs. 17.9% reduction). Hospital mortality declined in all subsets of women and men with
and without DM (Figure), with the greatest mortality improvement among women with DM
(30.9% reduction; p for trend<0.001)).
Conclusions: Between 1994-2002, MI hospital mortality declined among patients with
and without DM, associated with increasing use of evidence-based CV therapies.
Patients with DM had the greatest mortality improvement, and contrary to the earlier
NHANES findings, women with DM have recently experienced the greatest mortality
improvement.
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827-4 N Terminal Pro Brain Natriuretic Peptide Is the Most 
Powerful Predictor of Long-Term Mortality in Diabetic 
Patients With Acute Coronary Syndromes
Stefan Karl James, Mats Stridsberg, Per Venge, Paul Armstrong, Robert Califf, Maarten 
Simoons, Lars Wallentin, Institution of Medical Sciences, Uppsala, Sweden
Background: Acute coronary syndrome (ACS) patients with diabetes have increased
morbidity and mortality. The individual factors contributing to this are incompletely under-
stood.
Methods: We evaluated predictors of outcome in 1677 patients with diabetes in the inter-
national GUSTO IV trial that enrolled 7800 ACS patients without ST-elevation not sched-
uled for early revascularization.
Results:
The incidence of myocardial infarction at 30 days in patients with diabetes tended to be
higher than for non-diabetics; 6.4% vs. 5.3%, p=0.09. The mortality was however, almost
twice as high; at 30 days 6.0% vs. 3.2%, p<0.001) and at 1-year, 13.5% vs. 6.9%
p<0.001. On multivariate analysis including a large number of predictors of mortality, lev-
els of N-terminal proBrain Natriuretic (Nt-proBNP) peptide was the risk-indicator with the
strongest relation to long-term mortality.
Conclusion: In patients with diabetes mellitus and non-ST elevation ACS, mortality is
substantially increased. Also in diabetic patients the utilization of a multi-marker strategy
can select patients at highest risk for an intensified treatment.
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827-5 Diabetic Patients With Acute Myocardial Infarction Have 
Larger Infarct Size, Lower Ejection Fraction, and Higher 
Mortality
Jorge R. Alegria, Todd D. Miller, Raymond J. Gibbons, Qi-Long Yi, Salim Yusuf, Mayo 
Clinic, Rochester, MN, McMaster Clinic, Hamilton, ON, Canada
Introduction: Patients with diabetes mellitus (DM) with acute myocardial infarction (AMI)
have a higher mortality than non-diabetics (NoDM). The aim of this study was to examine
the relationships between mortality, left ventricular ejection fraction (LVEF), and infarct
size in patients with DM with AMI. Methods: In the Collaborative Organization of Rheo-
thRx Evaluation (CORE) Trial, subsets of patients underwent quantitative radionuclide
measurement of gated equilibrium LVEF (n=1139), Technetium-99m sestamibi infarct
size (n= 1167), or both (n=872) at days 6-16 following thrombolysis for AMI. Follow-up at
6 months was 96.7% complete. Results: The prevalence of DM in these patient subsets
was 16%-17%. Patients with DM had evidence for larger infarcts even after adjustment
baseline variables: mean LVEF 48% DM vs 51% NoDM (p=0.0021); infarct size (% of left
ventricle) 22% DM vs 17% NoDM (p=0.0396). The number of deaths was small in both
groups: LVEF subset = 21, infarct size subset = 27. Six-month mortality was higher in
patients with DM: LVEF subset 6% DM vs 1% NoDM; infarct size subset 6% DM vs 2%
NoDM. In the LVEF subset, both DM (p< 0.0001) and LVEF (p=0.0002) were indepen-
dent predictors of mortality; similarly, in the infarct size subset, DM (p=0.0028) and infarct
size ( p=0.0024) were independent predictors. Conclusions: Patients with DM with AMI
have lower LVEF and larger infarct size. Larger infarction only partially explains the
higher mortality in patients with DM, since DM itself was associated with higher 6-month
mortality independent of LVEF or infarct size.
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827-6 Underuse of Glycoprotein IIb/IIIa Receptor Blockers in 
Diabetics Undergoing Percutaneous Coronary 
Intervention for Acute Coronary Syndromes in Current 
Clinical Practice in Europe: Results of the International 
Shakespeare Registry
Anselm K. Gitt, Uwe Zeymer, Martin G. Gottwik, Jean-Pierre Bassand, Keith Dawkins, 
David Hasdai, Ricardo Seabra-Gomes, Andreij Cieslinski, Paolo Fioretti, Jochen Senges, 
The SHAKESPEARE-Study-Group, Herzzentrum Ludwigshafen, Ludwigshafen, 
Germany
Background: Meta-analysis of randomised trials using GP IIb/IIIa receptor blocker (GP
IIb/IIIa) in acute coronary syndromes (ACS) indicated a significant reduction of mortality
at 30 days in diabetic patients (pts) with ACS undergoing PCI.
Methods: Since February 2002 the international Shakespeare Registry has been enroll-
ing consecutive patients undergoing PCI in 7 different countries in Europe to document
interventional and medical treatment as well as outcome in clinical practice. We exam-
ined the use of GP Ib/IIIa in diabetics versus non-diabetics with ACS in clinical practice in
Diabetics Non-diabetics
Odds ratio
(95 % C.I)
Odds ratio
(95 % C.I)
Nt-proBNP > 669 ng/L 3.4 (2.3-5.7) 1.9 (1.4-2.6)
St-depression > 0.5 mm 1.9 (1.1-3.3) 1.2 (0.8-1.7)
Troponin-T > 0.01 ug/L 1.7 (1.0-2.9) 1.6 (1.1-2.3)
Creatinine clearance < 51ml/min 1.7 (1.2-2.5) 2.1 (1.6-2.8)
Previous MI 1.7(1.2-2.5) 1.5 (1.2-2.0)
